{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:28:34Z","timestamp":1794965314323,"version":"4.9.1"},"reference-count":84,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research, New Delhi, India","doi-asserted-by":"publisher","award":["ERP-2020-3391"],"award-info":[{"award-number":["ERP-2020-3391"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDRR"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>Psoriasis is an immune-mediated skin disease that leads to the initiation of abnormal production of inflammatory mediators and keratinocytes hyper-proliferation. Th-1 cell expressing cytokines such as IL-1\u03b2 and TNF-\u03b1 have been the important hallmarks in the management of psoriasis. However, investigations carried out in the previous few years underline the involvement of another subset of T helper cells, i.e. Th-17 in psoriasis exacerbation, and hence become the point of focus now. The immunopathogenesis of Th-17 is the result of the IL-23\/Th-17 axis. It involves the release of IL-17 and IL-22 in response to the activated NF-k\u03b2 dependent activation of IL-23. The function of human Th-17 cells as well as the crucial role of IL-23\/Th-17 axis in the exacerbation of psoriasis and treatment have been well explored. Therefore, considering IL-23\/Th17 axis as a pertinent therapeutic target in immune driven disorders, extensive investigations are now highlighting the utility of biopharmaceuticals and\/or biological agents acting on these targets. Here, we review the IL-23\/Th-17 axis based therapeutic targets, different types of active moieties based on their source of availability and most useful USFDA approved Mabs targeting the IL-23\/Th17 axis in psoriasis for a better understanding of the future possibilities in this area.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/2589977513666210707114520","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T23:53:06Z","timestamp":1625788386000},"page":"24-36","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["IL-23\/Th17 Axis: A Potential Therapeutic Target of Psoriasis"],"prefix":"10.2174","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8726-3959","authenticated-orcid":true,"given":"Vineet Kumar","family":"Rai","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab 142001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab 142001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak Kumar","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab 142001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanshyam Das","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab 142001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Kumar","family":"Narang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab 142001, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"Rachakonda T.D.","year":"2014","unstructured":"Rachakonda T.D.; Schupp C.W.; Armstrong A.W.; Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014,70(3),512-516","journal-title":"J Am Acad Dermatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013005268","volume":"30","author":"Raut A.S.","year":"2013","unstructured":"Raut A.S.; Prabhu R.H.; Patravale V.B.; Psoriasis clinical implications and treatment: A review. Crit Rev Ther Drug Carrier Syst 2013,30(3),183-216","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"E2514","DOI":"10.3390\/ijms18122514","volume":"18","author":"Boche\u0144ska K.","year":"2017","unstructured":"Boche\u0144ska K.; Smoli\u0144ska E.; Moskot M.; Jak&#xF3;bkiewicz-Banecka J.; Gabig-Cimi\u0144ska M.; Models in the research process of psoriasis. Int J Mol Sci 2017,18(12),E2514","journal-title":"Int J Mol Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","volume":"182","author":"van der Fits L.","year":"2009","unstructured":"van der Fits L.; Mourits S.; Voerman J.S.; Kant M.; Boon L.; Laman J.D.; Cornelissen F.; Mus A.M.; Florencia E.; Prens E.P.; Lubberts E.; Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J Immunol 2009,182(9),5836-5845","journal-title":"J Immunol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/cmi.2012.15","volume":"9","author":"Cai Y.","year":"2012","unstructured":"Cai Y.; Fleming C.; Yan J.; New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 2012,9(4),302-309","journal-title":"Cell Mol Immunol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e67078","DOI":"10.1371\/journal.pone.0067078","volume":"8","author":"Sun J.","year":"2013","unstructured":"Sun J.; Zhao Y.; Hu J.; Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PLoS One 2013,8(6),e67078","journal-title":"PLoS One"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","volume":"128","author":"Lowes M.A.","year":"2008","unstructured":"Lowes M.A.; Kikuchi T.; Fuentes-Duculan J.; Cardinale I.; Zaba L.C.; Haider A.S.; Bowman E.P.; Krueger J.G.; \nPsoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008,128(5),1207-1211","journal-title":"J Invest Dermatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"594735","DOI":"10.3389\/fimmu.2020.594735","volume":"11","author":"Liu T.","year":"2020","unstructured":"Liu T.; Li S.; Ying S.; Tang S.; Ding Y.; Li Y.; Qiao J.; Fang H.; The IL-23\/IL-17 pathway in inflammatory skin diseases: From bench to bedside. Front Immunol 2020,11(2971),594735","journal-title":"Front Immunol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.4049\/jimmunol.0900521","volume":"183","author":"Wang H.","year":"2009","unstructured":"Wang H.; Syrovets T.; Kess D.; B&#xFC;chele B.; Hainzl H.; Lunov O.; Weiss J.M.; Scharffetter-Kochanek K.; Simmet T.; Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. J Immunol 2009,183(7),4755-4763","journal-title":"J Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2133.2012.10949.x","volume":"167","author":"Karadag A.S.","year":"2012","unstructured":"Karadag A.S.; Ertugrul D.T.; Bilgili S.G.; Takci Z.; Akin K.O.; Calka O.; Immunoregulatory effects of isotretinoin in patients with acne. Br J Dermatol 2012,167(2),433-435","journal-title":"Br J Dermatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/jid.2011.53","volume":"131","author":"R&#xE1;cz E.","year":"2011","unstructured":"R&#xE1;cz E.; Prens E.P.; Kurek D.; Kant M.; de Ridder D.; Mourits S.; Baerveldt E.M.; Ozgur Z.; van IJcken W.F.; Laman J.D.; Staal F.J.; van der Fits L.; Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol 2011,131(7),1547-1558","journal-title":"J Invest Dermatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3389\/fimmu.2019.01440","volume":"10","author":"Zhang L.J.","year":"2019","unstructured":"Zhang L.J.; Type1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis. Front Immunol 2019,10,1440","journal-title":"Front Immunol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"Rendon A.","year":"2019","unstructured":"Rendon A.; Sch&#xE4;kel K.; Psoriasis pathogenesis and treatment. Int J Mol Sci 2019,20(6),1475","journal-title":"Int J Mol Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1038\/jid.2012.167","volume":"132","author":"Bergboer J.G.M.","year":"2012","unstructured":"Bergboer J.G.M.; Zeeuwen P.L.J.M.; Schalkwijk J.; Genetics of psoriasis: Evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Invest Dermatol 2012,132(10),2320-2331","journal-title":"J Invest Dermatol"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Rai V, Sharma A, Upadhyay D, Sarma G, Kaur N, Gupta G. Squalene integrated NLC based gel of tamoxifen citrate for efficient treatment of psoriasis: A preclinical investigation. J Drug Del Sci Technol 2020; 56: 101568.","DOI":"10.1016\/j.jddst.2020.101568"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-420130-9.00001-3","author":"Honari G.","year":"2014","unstructured":"Honari G.; Maibach H.;  Applied dermatotoxicology 2014,1-10","journal-title":"Applied dermatotoxicology"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1152\/advan.00066.2013","volume":"37","author":"Pennock N.D.","year":"2013","unstructured":"Pennock N.D.; White J.T.; Cross E.W.; Cheney E.E.; Tamburini B.A.; Kedl R.M.; T cell responses: Naive to memory and everything in between. Adv Physiol Educ 2013,37(4),273-283","journal-title":"Adv Physiol Educ"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"Lowes M.A.","year":"2014","unstructured":"Lowes M.A.; Su&#xE1;rez-Fari&#xF1;as M.; Krueger J.G.; Immunology of psoriasis. Annu Rev Immunol 2014,32,227-255","journal-title":"Annu Rev Immunol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/ijms20030739","volume":"20","author":"Georgescu S.R.","year":"2019","unstructured":"Georgescu S.R.; Tampa M.; Caruntu C.; Sarbu M.I.; Mitran C.I.; Mitran M.I.; Matei C.; Constantin C.; Neagu M.; Advances in understanding the immunological pathways in psoriasis. Int J Mol Sci 2019,20(3),739","journal-title":"Int J Mol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0019-5154.53175","volume":"54","author":"Raychaudhuri S.P.","year":"2009","unstructured":"Raychaudhuri S.P.; Raychaudhuri S.K.; Biologics: Target-specific treatment of systemic and cutaneous autoimmune diseases. Indian J Dermatol 2009,54(2),100-109","journal-title":"Indian J Dermatol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF02591635","volume":"21","author":"Romagnani S.","year":"1991","unstructured":"Romagnani S.; Type 1 T helper and type 2 T helper cells: Functions, regulation and role in protection and disease. Int J Clin Lab Res 1991,21(2),152-158","journal-title":"Int J Clin Lab Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4103\/0972-124X.82255","volume":"15","author":"Arun K.V.","year":"2011","unstructured":"Arun K.V.; Talwar A.; Kumar T.S.S.; T-helper cells in the etiopathogenesis of periodontal disease: A mini review. J Indian Soc Periodontol 2011,15(1),4-10","journal-title":"J Indian Soc Periodontol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00005-015-0362-x","volume":"63","author":"Yamagata T.","year":"2015","unstructured":"Yamagata T.; Skepner J.; Yang J.; Targeting Th17 effector cytokines for the treatment of autoimmune diseases. Arch Immunol Ther Exp (Warsz) 2015,63(6),405-414","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-015-0092-3","volume":"6","author":"Campa M.","year":"2016","unstructured":"Campa M.; Mansouri B.; Warren R.; Menter A.; A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb) 2016,6(1),1-12","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.dsi.2012.08.002","volume":"30","author":"Chiu H.Y.","year":"2012","unstructured":"Chiu H.Y.; Cheng Y.P.; Tsai T.F.; T helper type 17 in psoriasis: From basic immunology to clinical practice. Zhonghua Pifuke Yixue Zazhi 2012,30(4),136-141","journal-title":"Zhonghua Pifuke Yixue Zazhi"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00714.x","volume":"226","author":"Boniface K.","year":"2008","unstructured":"Boniface K.; Blom B.; Liu Y.J.; de Waal Malefyt R.; From interleukin-23 to T-helper 17 cells: Human T-helper cell differentiation revisited. Immunol Rev 2008,226,132-146","journal-title":"Immunol Rev"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11427-010-0045-0","volume":"53","author":"Tang F.","year":"2010","unstructured":"Tang F.; Du Q.; Liu Y.J.; Plasmacytoid dendritic cells in antiviral immunity and autoimmunity. Sci China Life Sci 2010,53(2),172-182","journal-title":"Sci China Life Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.antiviral.2012.01.011","volume":"93","author":"Martinez O.","year":"2012","unstructured":"Martinez O.; Leung L.W.; Basler C.F.; The role of antigen-presenting cells in filoviral hemorrhagic fever: Gaps in current knowledge. Antiviral Res 2012,93(3),416-428","journal-title":"Antiviral Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1084\/jem.20090480","volume":"206","author":"Ganguly D.","year":"2009","unstructured":"Ganguly D.; Chamilos G.; Lande R.; Gregorio J.; Meller S.; Facchinetti V.; Homey B.; Barrat F.J.; Zal T.; Gilliet M.; Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009,206(9),1983-1994","journal-title":"J Exp Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature04754","volume":"441","author":"Mangan P.R.","year":"2006","unstructured":"Mangan P.R.; Harrington L.E.; O\u2019Quinn D.B.; Helms W.S.; Bullard D.C.; Elson C.O.; Hatton R.D.; Wahl S.M.; Schoeb T.R.; Weaver C.T.; Transforming growth factor-&#x3B2; induces development of the T(H)17 lineage. Nature 2006,441(7090),231-234","journal-title":"Nature"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ni1497","volume":"8","author":"Wilson N.J.","year":"2007","unstructured":"Wilson N.J.; Boniface K.; Chan J.R.; McKenzie B.S.; Blumenschein W.M.; Mattson J.D.; Basham B.; Smith K.; Chen T.; Morel F.; Lecron J.C.; Kastelein R.A.; Cua D.J.; McClanahan T.K.; Bowman E.P.; de Waal Malefyt R.; Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007,8(9),950-957","journal-title":"Nat Immunol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.immuni.2007.11.016","volume":"28","author":"Yang X.O.","year":"2008","unstructured":"Yang X.O.; Pappu B.P.; Nurieva R.; Akimzhanov A.; Kang H.S.; Chung Y.; Ma L.; Shah B.; Panopoulos A.D.; Schluns K.S.; Watowich S.S.; Tian Q.; Jetten A.M.; Dong C.; T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008,28(1),29-39","journal-title":"Immunity"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","volume":"126","author":"Ivanov I.I.","year":"2006","unstructured":"Ivanov I.I.; McKenzie B.S.; Zhou L.; Tadokoro C.E.; Lepelley A.; Lafaille J.J.; Cua D.J.; Littman D.R.; The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006,126(6),1121-1133","journal-title":"Cell"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PTT.S98893","volume":"8","author":"Fotiadou C.","year":"2018","unstructured":"Fotiadou C.; Lazaridou E.; Sotiriou E.; Ioannides D.; Targeting IL-23 in psoriasis: Current perspectives. Psoriasis (Auckl) 2018,8,1-5","journal-title":"Psoriasis (Auckl)"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/jid.2009.59","volume":"129","author":"Di Cesare A.","year":"2009","unstructured":"Di Cesare A.; Di Meglio P.; Nestle F.O.; The IL-23\/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009,129(6),1339-1350","journal-title":"J Invest Dermatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"Hori S.","year":"2003","unstructured":"Hori S.; Nomura T.; Sakaguchi S.; Control of regulatory T cell development by the transcription factor Foxp3. Science 2003,299(5609),1057-1061","journal-title":"Science"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.15570\/actaapa.2018.4","volume":"27","author":"Owczarczyk-Saczonek A.","year":"2018","unstructured":"Owczarczyk-Saczonek A.; Czerwi\u0144ska J.; Placek W.; The role of regulatory T cells and anti-inflammatory cytokines in psoriasis. Acta Dermatovenerol Alp Panonica Adriat 2018,27(1),17-23","journal-title":"Acta Dermatovenerol Alp Panonica Adriat"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5114\/ada.2017.69305","volume":"34","author":"Nedoszytko B.","year":"2017","unstructured":"Nedoszytko B.; Lange M.; Soko\u0142owska-Wojdy\u0142o M.; Renke J.; Trzonkowski P.; Sobjanek M.; Szczerkowska-Dobosz A.; Niedoszytko M.; G&#xF3;rska A.; Romantowski J.; Skokowski J.; Kalinowski L.; Nowicki R.; The role of regulatory T cells and genes involved in their differentiation in pathogenesis of selected inflammatory and neoplastic skin diseases. Part I: Treg properties and functions. Postepy Dermatol Alergol 2017,34(4),285-294","journal-title":"Postepy Dermatol Alergol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"Brembilla N.C.","year":"2018","unstructured":"Brembilla N.C.; Senra L.; Boehncke W-H.; The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol 2018,9,1682","journal-title":"Front Immunol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jaci.2015.01.033","volume":"136","author":"Mashiko S.","year":"2015","unstructured":"Mashiko S.; Bouguermouh S.; Rubio M.; Baba N.; Bissonnette R.; Sarfati M.; Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J Allergy Clin Immunol 2015,136(2),351-9.e1","journal-title":"J Allergy Clin Immunol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1189\/jlb.0212101","volume":"92","author":"Elloso M.M.","year":"2012","unstructured":"Elloso M.M.; Gomez-Angelats M.; Fourie A.M.; Targeting the Th17 pathway in psoriasis. J Leukoc Biol 2012,92(6),1187-1197","journal-title":"J Leukoc Biol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/00054725-199911000-00009","volume":"5","author":"Romagnani S.","year":"1999","unstructured":"Romagnani S.; Th1\/Th2 cells. Inflamm Bowel Dis 1999,5(4),285-294","journal-title":"Inflamm Bowel Dis"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"a016303","DOI":"10.1101\/cshperspect.a016303","volume":"7","author":"Sokol C.L.","year":"2015","unstructured":"Sokol C.L.; Luster A.D.; The chemokine system in innate immunity. Cold Spring Harb Perspect Biol 2015,7(5),a016303","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=44","doi-asserted-by":"publisher","unstructured":"Diani M, Altomare G, Reali E. T Helper cell subsets in clinical manifestations of psoriasis. J Immunol Res 2016; 2016: 7692024.","DOI":"10.1155\/2016\/7692024"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"Hawkes J.E.","year":"2017","unstructured":"Hawkes J.E.; Chan T.C.; Krueger J.G.; Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol 2017,140(3),645-653","journal-title":"J Allergy Clin Immunol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2174\/187152812800392805","volume":"11","author":"Toussirot E.","year":"2012","unstructured":"Toussirot E.; The IL23\/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 2012,11(2),159-168","journal-title":"Inflamm Allergy Drug Targets"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"CD007572","DOI":"10.1002\/14651858.CD007572.pub3","volume":"11","author":"MacDonald J.K.","year":"2016","unstructured":"MacDonald J.K.; Nguyen T.M.; Khanna R.; Timmer A.; Anti-IL-12\/23p40 antibodies for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev [-CD.].2016,11(11),CD007572","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.sder.2010.02.001","volume":"29","author":"Gandhi M.","year":"2010","unstructured":"Gandhi M.; Alwawi E.; Gordon K.B.; Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg 2010,29(1),48-52","journal-title":"Semin Cutan Med Surg"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4161\/mabs.1.3.8593","volume":"1","author":"Cingoz O.","year":"2009","unstructured":"Cingoz O.; Ustekinumab. MAbs 2009,1(3),216-221","journal-title":"MAbs"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","volume":"135","author":"Sandborn W.J.","year":"2008","unstructured":"Sandborn W.J.; Feagan B.G.; Fedorak R.N.; Scherl E.; Fleisher M.R.; Katz S.; Johanns J.; Blank M.; Rutgeerts P.; A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn\u2019s disease. Gastroenterology 2008,135(4),1130-1141","journal-title":"Gastroenterology"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/01.ibd.0000225337.14356.31","volume":"12","author":"Burakoff R.","year":"2006","unstructured":"Burakoff R.; Barish C.F.; Riff D.; Pruitt R.; Chey W.Y.; Farraye F.A.; Shafran I.; Katz S.; Krone C.L.; Vander Vliet M.; Stevens C.; Sherman M.L.; Jacobson E.; Bleday R.; A phase 1\/2A trial of STA 5326, an oral interleukin-12\/23 inhibitor, in patients with active moderate to severe Crohn\u2019s disease. Inflamm Bowel Dis 2006,12(7),558-565","journal-title":"Inflamm Bowel Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/jid.2011.304","volume":"132","author":"Gordon K.B.","year":"2012","unstructured":"Gordon K.B.; Langley R.G.; Gottlieb A.B.; Papp K.A.; Krueger G.G.; Strober B.E.; Williams D.A.; Gu Y.; Valdes J.M.; A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012,132(2),304-314","journal-title":"J Invest Dermatol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"Leonardi C.L.","year":"2008","unstructured":"Leonardi C.L.; Kimball A.B.; Papp K.A.; Yeilding N.; Guzzo C.; Wang Y.; Li S.; Dooley L.T.; Gordon K.B.; Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008,371(9625),1665-1674","journal-title":"Lancet"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"Papp K.A.","year":"2008","unstructured":"Papp K.A.; Langley R.G.; Lebwohl M.; Krueger G.G.; Szapary P.; Yeilding N.; Guzzo C.; Hsu M.C.; Wang Y.; Li S.; Dooley L.T.; Reich K.; Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008,371(9625),1675-1684","journal-title":"Lancet"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2230.1996.tb00142.x","volume":"21","author":"Boffa M.J.","year":"1996","unstructured":"Boffa M.J.; Chalmers R.J.; Methotrexate for psoriasis. Clin Exp Dermatol 1996,21(6),399-408","journal-title":"Clin Exp Dermatol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5114\/pdia.2014.47121","volume":"31","author":"Czarnecka-Operacz M.","year":"2014","unstructured":"Czarnecka-Operacz M.; Sadowska-Przytocka A.; The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge. Postepy Dermatol Alergol 2014,31(6),392-400","journal-title":"Postepy Dermatol Alergol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"805705","DOI":"10.1155\/2013\/805705","volume":"2013","author":"Colombo M.D.","year":"2013","unstructured":"Colombo M.D.; Cassano N.; Bellia G.; Vena G.A.; Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal 2013,2013,805705","journal-title":"ScientificWorldJournal"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/0190-9622(90)70360-T","volume":"23","author":"Cooper K.D.","year":"1990","unstructured":"Cooper K.D.; Voorhees J.J.; Fisher G.J.; Chan L.S.; Gupta A.K.; Baadsgaard O.; Effects of cyclosporine on immunologic mechanisms in psoriasis. J Am Acad Dermatol 1990,23(6 Pt 2),1318-1326","journal-title":"J Am Acad Dermatol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.4049\/jimmunol.180.3.1913","volume":"180","author":"Haider A.S.","year":"2008","unstructured":"Haider A.S.; Lowes M.A.; Su&#xE1;rez-Fari&#xF1;as M.; Zaba L.C.; Cardinale I.; Khatcherian A.; Novitskaya I.; Wittkowski K.M.; Krueger J.G.; Identification of cellular pathways of &#x201C;type 1,&#x201D; Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008,180(3),1913-1920","journal-title":"J Immunol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/14712598.2019.1555235","volume":"19","author":"Silfvast-Kaiser A.","year":"2019","unstructured":"Silfvast-Kaiser A.; Paek S.Y.; Menter A.; Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther 2019,19(1),45-54","journal-title":"Expert Opin Biol Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/11538950-000000000-00000","volume":"12","author":"Kurzeja M.","year":"2011","unstructured":"Kurzeja M.; Rudnicka L.; Olszewska M.; New interleukin-23 pathway inhibitors in dermatology: Ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol 2011,12(2),113-125","journal-title":"Am J Clin Dermatol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","volume":"68","author":"Kim J.","year":"2017","unstructured":"Kim J.; Krueger J.G.; Highly effective new treatments for psoriasis target the IL-23\/Type 17 T cell autoimmune axis. Annu Rev Med 2017,68,255-269","journal-title":"Annu Rev Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/1759720X17735756","volume":"9","author":"Tsai Y.C.","year":"2017","unstructured":"Tsai Y.C.; Tsai T.F.; Anti-interleukin and interleukin therapies for psoriasis: Current evidence and clinical usefulness. Ther Adv Musculoskelet Dis 2017,9(11),277-294","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3410\/M1-30","volume":"1","author":"Yost J.","year":"2009","unstructured":"Yost J.; Gudjonsson J.E.; The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. F1000 Med Rep 2009,1,30","journal-title":"F1000 Med Rep"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.jss.2012.10.050","volume":"180","author":"Huo M.","year":"2013","unstructured":"Huo M.; Cui X.; Xue J.; Chi G.; Gao R.; Deng X.; Guan S.; Wei J.; Soromou L.W.; Feng H.; Wang D.; Anti-inflammatory effects of linalool in RAW 264.7 macrophages and lipopolysaccharide-induced lung injury model. J Surg Res 2013,180(1),e47-e54","journal-title":"J Surg Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3389\/fmed.2018.00184","volume":"5","author":"Ibbotson S.H.","year":"2018","unstructured":"Ibbotson S.H.; A perspective on the use of NB-UVB phototherapy vs. PUVA photochemotherapy. Front Med (Lausanne) 2018,5,184","journal-title":"Front Med (Lausanne)"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1038\/jid.2010.166","volume":"130","author":"Johnson-Huang L.M.","year":"2010","unstructured":"Johnson-Huang L.M.; Su&#xE1;rez-Fari&#xF1;as M.; Sullivan-Whalen M.; Gilleaudeau P.; Krueger J.G.; Lowes M.A.; Effective narrow-band UVB radiation therapy suppresses the IL-23\/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 2010,130(11),2654-2663","journal-title":"J Invest Dermatol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.4049\/jimmunol.0903719","volume":"184","author":"Singh T.P.","year":"2010","unstructured":"Singh T.P.; Sch&#xF6;n M.P.; Wallbrecht K.; Michaelis K.; Rinner B.; Mayer G.; Schmidbauer U.; Strohmaier H.; Wang X.J.; Wolf P.; 8-methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23\/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010,184(12),7257-7267","journal-title":"J Immunol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"E2684","DOI":"10.3390\/ijms18122684","volume":"18","author":"Woo Y.R.","year":"2017","unstructured":"Woo Y.R.; Cho D.H.; Park H.J.; Molecular mechanisms and management of a cutaneous inflammatory disorder: Psoriasis. Int J Mol Sci 2017,18(12),E2684","journal-title":"Int J Mol Sci"},{"key":"ref=70","doi-asserted-by":"crossref","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol 2018; 201(6): 1605-13.","DOI":"10.4049\/jimmunol.1800013"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1517\/14728222.2014.889686","volume":"18","author":"Chiricozzi A.","year":"2014","unstructured":"Chiricozzi A.; Saraceno R.; Chimenti M.S.; Guttman-Yassky E.; Krueger J.G.; Role of IL-23 in the pathogenesis of psoriasis: A novel potential therapeutic target? Expert Opin Ther Targets 2014,18(5),513-525","journal-title":"Expert Opin Ther Targets"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"Glatt S.","year":"2018","unstructured":"Glatt S.; Baeten D.; Baker T.; Griffiths M.; Ionescu L.; Lawson A.D.G.; Maroof A.; Oliver R.; Popa S.; Strimenopoulou F.; Vajjah P.; Watling M.I.L.; Yeremenko N.; Miossec P.; Shaw S.; Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis 2018,77(4),523-532","journal-title":"Ann Rheum Dis"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/ijms18112297","volume":"18","author":"R&#xF8;nholt K.","year":"2017","unstructured":"R&#xF8;nholt K.; Iversen L.; Old and new biological therapies for psoriasis. Int J Mol Sci 2017,18(11),2297","journal-title":"Int J Mol Sci"},{"key":"ref=74","first-page":"1","volume":"70","author":"Thappa D.M.","year":"2004","unstructured":"Thappa D.M.; Laxmisha C.; Immunomodulators in the treatment of psoriasis. Indian J Dermatol Venereol Leprol 2004,70(1),1-9","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","volume":"3","author":"Benson J.M.","year":"2011","unstructured":"Benson J.M.; Peritt D.; Scallon B.J.; Heavner G.A.; Shealy D.J.; Giles-Komar J.M.; Mascelli M.A.; Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs 2011,3(6),535-545","journal-title":"MAbs"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/j.1476-5381.2010.00702.x","volume":"160","author":"Weger W.","year":"2010","unstructured":"Weger W.; Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010,160(4),810-820","journal-title":"Br J Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"212594","DOI":"10.7573\/dic.212594","volume":"8","author":"Nogueira M.","year":"2019","unstructured":"Nogueira M.; Torres T.; Guselkumab for the treatment of psoriasis - evidence to date. Drugs Context 2019,8,212594","journal-title":"Drugs Context"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/PTT.S146640","volume":"8","author":"Beck K.M.","year":"2018","unstructured":"Beck K.M.; Sanchez I.M.; Yang E.J.; Liao W.; Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: Evidence to date. Psoriasis (Auckl) 2018,8,49-58","journal-title":"Psoriasis (Auckl)"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.2147\/DDDT.S167149","volume":"12","author":"Haugh I.M.","year":"2018","unstructured":"Haugh I.M.; Preston A.K.; Kivelevitch D.N.; Menter A.M.; Risankizumab: An anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther 2018,12,3879-3883","journal-title":"Drug Des Devel Ther"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"212570","DOI":"10.7573\/dic.212570","volume":"8","author":"Foulkes A.C.","year":"2019","unstructured":"Foulkes A.C.; Warren R.B.; Brodalumab in psoriasis: Evidence to date and clinical potential. Drugs Context 2019,8,212570","journal-title":"Drugs Context"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/14712598.2020.1729736","volume":"20","author":"Craig S.","year":"2020","unstructured":"Craig S.; Warren R.B.; Ixekizumab for the treatment of psoriasis: Up-to-date. Expert Opin Biol Ther 2020,20(6),549-557","journal-title":"Expert Opin Biol Ther"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/sj.jidsymp.5650037","volume":"12","author":"Tan J.K.","year":"2007","unstructured":"Tan J.K.; Aphale A.; Malaviya R.; Sun Y.; Gottlieb A.B.; Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc 2007,12(1),38-45","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2147\/TCRM.S3094","volume":"4","author":"Leman J.","year":"2008","unstructured":"Leman J.; Burden A.; Treatment of severe psoriasis with infliximab. Ther Clin Risk Manag 2008,4(6),1165-1176","journal-title":"Ther Clin Risk Manag"},{"key":"ref=84","first-page":"93","volume":"1","author":"Vena G.A.","year":"2007","unstructured":"Vena G.A.; Cassano N.; Drug focus: Adalimumab in the treatment of moderate to severe psoriasis. Biologics 2007,1(2),93-103","journal-title":"Biologics"}],"container-title":["Current Drug Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2589977513666210707114520","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/194560\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/2589977513666210707114520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T03:42:55Z","timestamp":1666323775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/194560\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/2589977513666210707114520","relation":{},"ISSN":["2589-9775"],"issn-type":[{"value":"2589-9775","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}